2022
Peters N, Wohlfahrt P, Hofmann C, Möhler C, Menkel S, Tschiche M, Krause M, Troost EGC, Enghardt W, Richter C. Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction. Radiother Oncol 2022; 166:71-78.
2021
Hessen ED, Makocki S, van der Heide UA, Jasperse B, Lutkenhaus LJ, Lamers E, Damen E, Troost EGC, Borst GR. The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials. Radiother Oncol 2021;164:202-208.
Süveg K, Le Pechoux C, Faivre-Finn C, Putora PM, De Ruysscher D, Widder J, Van Houtte P, Troost EGC, Slotman BJ, Ramella S, Pöttgen C, Peeters STH, Nestle U, McDonald F, Dziadziuszko R, Belderbos J, Ricardi U, Manapov F, Lievens Y, Geets X, Dieckmann K, Guckenberger M, Andratschke N, Glatzer M. Role of postoperative radiotherapy in the management for resected NSCLC – Decision criteria in clinical routine pre- and post-LungART. Clinical Lung cancer 2021;22(6):579-586.
Troost EGC, Menkel M, Tschiche M, Thiele J, Jaster M, Haak D, Kunath D. Towards online adaptive proton therapy: first report of plan-library-based plan-of-the-day approach. Acta Oncol 2021; doi: 10.1080/0284186X.2021.1994154.
Büttner M, Cordes N, Gauer T, Habermehl D, Klautke G, Micke O, Mäurer M, Sokoll J, Troost EGC, Christiansen H, Niyazi M. Current status and developments of German curriculum-based residency training programmes in radiation oncology. Radiat Oncol 2021;16:55.
Docea R, Pfeiffer M, Bodenstedt S, Kolbinger FR, Höller L, Wittig I, Hoffmann RT, Troost EGC, Riediger C, Weitz J, Speidel S. Simultaneous localisation and mapping for laparoscopic liver navigation: a comparative evaluation study. Proc. SPIE 11598, Medical Imaging 2021: Image-Guided Procedures, Robotic Interventions, and Modeling, 115980B.
Dünger L, Seidlitz A, Jentsch C, Platzek I, Kotzerke J, Beuthien-Baumann B, Baumann M, Krause M, Troost EGC, Raschke F. Reduced diffusion in white matter after radiotherapy with photons and protons. Radiother Oncol 2021;164:66-72.
Dutz A, Lühr A, Agolli L, Bütof R, Valentini C, Troost EGC, Baumann M, Vermeren X, Geismar D, Lamba N, Lebow EF, Bussière M, Daly JE, Bussière MR, Krause M, Timmermann B, Shih HA, Löck S. Modelling of late side effects following cranial proton beam therapy. Radiother Oncol 2021;157:15-23.
Dutz A, Lühr A, Troost EGC, Agolli L, Bütof R, Valentini C, Baumann M, Vermeren X, Geismar D, Timmermann B, Krause M, Löck S. Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. Radiother Oncol 2021;160:69-77.
Eekers DBP, di Perri D, Roelofs E, Postma A, Dijkstra J, Ajithkumar T, Alapetite C, Blomstrand M, Burnet NG, Calugaru V, Compter I, Coremans IEM, Harrabi S, Iannalfi A, Klaver YLB, Lambrecht M, Méndez Romero A, Paulsen F, Timmermann B, Vitek P, van der Weide HL, Whitfield GA, Nyström PW, Zindler J, de Ruysscher D, Langendijk J, Weber DC, Troost EGC, on behalf of the taskforce “European Particle Therapy Network” of ESTRO. Update of the EPTN atlas for CT- and MR-based (3T and 7T) contouring in Neuro-Oncology. Radiotherapy and Oncology 2021;160:259-265.
Gillmann C, Homolka N, Johnen W, Runz A, Echner G, Pfaffenberger A, Mann P, Schneider V, Hoffmann AL, Troost EGC, Koerber SA, Kotzerke J, Beuthien-Baumann B. ADAM PETer – an anthropomorphic, deformable and multimodality pelvis phantom with positron emission tomography extension for radiotherapy. Medical Physics 2021; 48:1624-1632.
Glatzer M, Faivre-Finn C, De Ruysscher D, Widder J, Van Houtte P, Troost EGC, Slotman BJ, Ramella S, Pöttgen C, Peeters STH, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Ricardi U, Manapov F, Lievens Y, Geets X, Dieckmann K, Guckenberger M, Andratschke N, Süveg K, Putora PM. Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiother Oncol 2021;154:269-273.
Gommlich A, Raschke F, Petr J, Seidlitz A, Jentsch C, Platzek I, van den Hoff J, Kotzerke J, Beuthien-Baumann B, Baumann M, Krause M, Troost EGC. Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy. Magnetic Resonance Materials in Physics, Biology and Medicine 2021; doi 10.1007/s10334-021-00922-3.
In ’t Ven L, Roelofs E, Cubillos Mesías M, Compter I, Klaver Y, Smeenk RJ, Janssens GOR, Kaanders JHAM, Fajardo RD, Oldenburger F, de Ruysscher D, Troost EGC, Eekers D. ROCOCO Performance Score translates dosimetric differences into clinically relevant endpoints: comparing IMPT to VMAT in pilocytic astrocytoma. ctRO 2021;28:32-38.
Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC on behalf of “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”. Value of PET imaging for radiation therapy. Nuklearmedizin 2021; doi: 10.1055/a-1525-7029.
Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC on behalf of “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021; 127:1-23.
Loizeau M, Fabiano S, Papp D, Stützer K, Jakobi A, Bandurska-Luque A, Troost EGC, Richter C, Unkelbach J. Optimal allocation of proton therapy slots in combined proton-photon radiotherapy. Int J Radiat Oncol Biol Phys 2021;111(1):196-207.
Meneghetti AR, Zwanenburg A, Leger S, Leger K, Troost EGC, Linge A, Lohaus F, Schreiber A, Kalinauskaite G, Tinhofer I, Guberina N, Guberina M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Böke S, Zips D, Krause M, BaumannM, Löck S. Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. ctRO 2021;26:62-70.
Stefanowicz S, Wlodarczyk W, Frosch S, Zschaeck S, Troost EGC. Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: gastrointestinal organs remain critical. ctRO 2021;27:24-31.
Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol 2021;156:102-112.
van Limbergen EJ, Hoeben A, Lieverse R, Houben R, Overhof C, Jacobi L, Postma A, Zindler J, Verhelst F, Dubois LJ, de Ruysscher D, Troost EGC, Lambin P. Toxicity of L19-Interleukin 2 combined with Stereotactic Body Radiotherapy: A phase I study. Int. Journal of Radiation Oncology, Biology, Physics 2021;109(5):1421-1430.
Witzmann K, Raschke F, Troost EGC. MR image changes of normal-appearing brain tissue after radiotherapy. Cancers 2021;13:1573.
Zschaeck S, Zöphel K, Seidlitz A, Zips D, Kotzerke J, Baumann M, Troost EGC, Löck S, Krause M. Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/ glucose uptake in head and neck cancer. Radiotherapy and Oncology 2021;155:204-211.
2020
Cubillos-Mesías M, Troost EGC, Lohaus F, Agolli L, Rehm M, Richter C, Stützer K. Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy. Br J Radiol 2020;92:20190573.
den Otter LA, Anakotta RM, Weessies M, Roos CTG, Sijtsema NM, Muijs CT, Dieters M, Wijsman R, Troost EGC, Richter C. Investigation of inter-fraction target motion variations in the context of pencil beam scanned proton therapy in non-small cell lung cancer patients. Medical Physics 2020; 47(9):3835–3844.
Garibaldi C, Jornet N, Tan LT, Bojen A, Franco P, Bussink J, Troost EGC, Bak B, Bibault JE, Dzhugashvili M, van den Berge L, Fizaine L, Leci A, Ricardi U, Jereczek-Fossa BA. National societies' needs as assessed by the ESTRO National Society Committee survey: a European perspective. Radiother Oncol 2020;151:176-181.
Glatzer M, Faivre-Finn C, De Ruysscher D, Widder J, Van Houtte P, Troost EGC, Dahele M, Slotman BJ, Ramella S, Pöttgen C, Peeters S, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Putora PM. Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice. Radiother Oncol 2020;150:26-29.
Leger, S, Zwanenburg A, Leger K, Lohaus F, Linge A, Schreiber A, Kalinauskaite G, Tinhofer I, Guberina N, Guberina M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Böke S, Zips D, Richter C, Krause M, Baumann M, Troost EGC, Löck S. Compehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC. Cancers 2020;12(10):3047.
Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM, Chauvet B, Coffey M, Coza O, Daisne J, Hadjieva T, Jarusevicius L, Karadjinovic V, Kouloulias V, Kozma E, Kristensen BH, Lopez AM, Malicki J, Minn H, Mohammed N, Petera J, Rolles M, Roques T, Russi E, Sedlmayer F, Slobina E, Smichkoska S, Takácsi-Nagy Z, Trigo L, Troost EGC, Untereiner M, Valgma M, van Loon J. How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol 2020;21(1):e42-e54.
Lieverse RIY, van Limbergen EJ, Oberije C, Troost EGC, Hadrup S, Dingemans A, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong M, Hendriks L, Bussink J, Geets X, Valentini V, Elia G, Nerio D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, de Ruysscher D, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy (SABR) combined with Immunotherapy (L19-IL2) in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer 2020;20:557.
Putora PM, De Ruysscher D, Glatzer M, Widder J, Van Houtte P, Troost EGC, Slotman BJ, Ramella S, Pöttgen C, Peeters S, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Faivre-Finn C. The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: patient selection among ESTRO experts. Radiother Oncol 2020;145:45-48.
Putora PM, Fischer G, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadiuszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman BJ, Troost EGC, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiother Oncol 2020;149:84-88.
Raschke F, Seidlitz A, Wesemann T, Löck S, Jentsch C, Platzek I, Petr J, van den Hoff J, Kotzerke J, Beuthien-Baumann B, Baumann M, Linn J, Krause M, Troost EGC. Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. Radiother Oncol 2020;150:262-267.
Starke S, Leger S, Zwanenburg A, Pilz K, Lohaus F, Linge A, Zophel K, Kotzerke J, Schreiber A, Tinhofer I, Budach V, Stuschke M, Balermpas P, Rodel C, Ganswindt U, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Richter C, Troost EGC, Krause M, Baumann M, Löck S. 2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports 2020;10:15625.
Taeubert L, Berker Y, Beuthien-Baumann B, Hoffmann AL, Troost EGC, Kachelrieß M, Gillmann C. CT-based attenuation correction of whole-body radiotherapy treatment positioning devices in PET/MRI hybrid imaging. Phys Med Biol 2020;65:23NT02.
Troost EGC, Wink KCJ, Roelofs E, Simone CB, Makocki S, Löck S, van Kollenburg P, Dechambre D, Minken AWH, van der Stoep J, Avery S, Jansen N, Solberg T, Bussink J, Dirk de Ruysscher D. Photons or protons for re-irradiation in (non-)small cell lung cancer? Results of the multicentric ROCOCO in silico study. B J Radiol 2020;92:20190879.
Unkelbach J, Bortfeld T, Cardenas CE, Gregoire V, Hager W, Heijmen B, Jeraj R, Korreman SS, Ludwig R, Pouymayou B, Shusharina N, Söderberg J, Toma-Dasu I, Troost EGC, Osorio EV. The role of computational methods for automating and improving clinical target volume definition. Radiotherapy and Oncology 2020;153:15-25.
van Herk M, Osorio EV, Troost EGC. Is reducing irradiated margins key to improving outcomes for radiotherapy? Lancet Oncol 2019;20(9):1208-1210.
Wohlfahrt P, Möhler C, Enghardt W, Krause M, Kunath D, Menkel S, Troost EGC, Greilich S, Richter C. Refinement of the Hounsfield look-up table by retrospective application of patient-specific direct proton stopping-power prediction from dual-energy CT. Medical Physics 2020;47(4):1796-1806.
Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K, Polster H, Troost EGC, Abolmaali N, Weitz J, Baumann M, Saeger HD, Grützmann R. Evaluation of response by FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer – a non-randomized, monocentric phase II clinical trial – PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther Onkol 2020;197:19-26.
Zschaeck S, Löck S, Hofheinz F, Zips D, Mortensen LS, Zöphel K, Troost EGC, Boeke D, Saksoe M, Mönnich D, Seidlitz A, Johansen J, Skripcak T, Gregoire V, Overgaard J, Baumann M, Krause M. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiother Oncol 2020;149:189-196.
Zschaeck S, Li Y, Bütof R, Lili C, Hua W, Troost EGC, Beck M, Amthauer H, Kaul D, Kotzerke J, Baur A, Ghadjar P, Baumann M, Krause M, Hofheinz F. Combined tumor plus non-tumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. Int J Cancer 2020;147(5):1427-1436.
Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini M, Buvat I, Cook G, Davatzikos C, Depeursinge A, Desseroit M-C, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Guckenberger M, Götz M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Fernandez JS, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C*, Löck S. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 2020;295(2):328-338.
Selected publications from 2019 and earlier
Apolle R, Brückner S, Frosch S, Rehm M, Thiele J, Valentini C, Lohaus F, Babatz J, Aust DE, Hampe J, Troost EGC. Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma. Radiother Oncol 2019;133:28-34. [Cited by: 0]
Apolle R, Appold S, Bijl HP, Blanchard P, Bussink J, Faivre-Finn C, Khalifa J, Laprie A, Lievens Y, Madani I, Ruffier A, de Ruysscher A, van Elmpt W, Troost EGC. Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. Acta Oncol 2019;58(10):1378-1385.
Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GBm Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M*, Troost EGC*. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene signatures for locally advanced HNSCC treated by primary radiochemotherapy. Radiat Oncol 2019;135:43-50. (*shared last authorship)
Wohlfahrt P, Möhler C, Troost EGC, Greilich S, Richter C. Dual-energy computed tomography to assess intra- and inter-patient tissue variability for proton treatment planning of brain tumor patients. Int J Radiat Oncol Biol Phys 2019;105(3):504-513.
Eekers DBP, in ‘t Veld L, Roelofs E, Postma A, Alapetite A, Burnet NG, Calugaru V, Compter I, Coremans IEM, Høyer M, Lambrecht M, Mendez A, Paulsen F, Perpar A, de Ruysscher D, Renard L, Vitek P, Weber DC, van der Weide HL, Whitfield GA, Wiggenraad R, Witt Nyström P, Zimmerman B, Troost EGC, on behalf of the taskforce “European Particle Therapy Network” of ESTRO. The EPTN consensus-based atlas for CT- and MR-based contouring in Neuro-Oncology. Radiother Oncol 2018;128(1):37-43.
Lambrecht M, Eekers DBP, Burnet NG, Calugar V, Coremans IEM, Fossati P, Høyer M, Méndez Romero A, Perpar A, de Ruysscher D, Timmermann B, Vitek P, Weber DC, van der Weide HL, Whitfield GA, Wiggenraad R, Roelofs E, Witt Nyström P, Troost EGC, on behalf of work package 1 of the taskforce “European Particle Therapy Network” of ESTRO. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiother Oncol 2018;128(1):26-36.
Langendijk JA, Orrechhia R, Haustermans K, Zips D, Balosso J, Lievens Y, Weber DC, Grau C, Troost EGC. Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol 2018;128(1):9-13.
Zindler JD, Hahn S, Thomas CR, Hoffman AL, Troost EGC, Lambin P. Increasing the therapeutic ratio of stereotactic ablative radiotherapy by individualized isotoxic dose prescription. J Nat Cancer Inst 2016;108(2):djv305.
Hoeben BAW*, Troost EGC*, Span PN, van Herpen CML, Bussink J, Oyen WJG, Kaanders JHAM. 18FLT-PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 2013;54(4):532-40; (*shared first author)
Troost EGC, Bussink J, Hoffmann AL, Boerman OC, Oyen WJG, Kaanders JHAM. 18FLT-PET-CT for early response monitoring and dose escalation in oropharyngeal tumor. J Nucl Med 2010;51(6):866-874.
Troost EGC, Bussink J, Slootweg PJ, Peeters WJM, Merkx MAW, van der Kogel AJ, Oyen WJG, Kaanders JHAM. Histopathologic validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med 2010;51(5):713-719.
